Xeris Biopharma Holdings

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. It engages in developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing's syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xeris Biopharma Holdings Inc. is making strong progress on the top line and is on track to achieve a positive cash flow breakeven point in 2023. The company holds a substantial number of patents globally, contributing to its success in the pharmaceutical industry. Xeris Pharmaceuticals' notable product, Gvoke, has experienced significant market share expansion, providing reassurance for potential investors.

Xeris Biopharma Holdings: On Track To Be Cash Flow Positive

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on Thursday, September 28, 2023 at 3:00pm Eastern Time. A live webcast of the event will be avail.

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

Akebia Therapeutics

Esperion Therapeutics

If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.

3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30am Eastern Time. A live webcast of the event will be available on the.

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Xeris Biopharma reports notable revenue growth in Q2 2023 for its main products, Gvoke, Keveyis, and Recorlev. The company's expenses have also increased, with a rise in the cost of goods sold and research and development expenses. Xeris has a satisfactory reserve for short-term needs but carries significant long-term debt, which may deter some investors.

Xeris Biopharma's Financial Pathway: Growth Amid Challenges

Xeris Biopharma has reported another quarter of record revenue driven by continued strong demand for the biopharmaceutical company's products Gvoke, Keveyis, and Recorlev. For the quarter which ended on June 30, 2023, the company achieved sales of $38 million, up 50% year-over-year and 14% sequentially.

Xeris Biopharma achieves record 2Q revenue and tightens full-year guidance

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman and Chief Executive Oﬃcer Steven Pieper - Chief Financial Oﬃcer Conference Call Participants Oren Livnat - H. C. Wainwright Glen Santangelo - Jefferies Operator Good morning all.

Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Earnings Call Transcript

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2023 and corporate highlights. “We posted another record quarter of revenue due to the continued strong demand of all three products, as well as contributions from our partner.

Xeris Biopharma Reports Second Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, August 8, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t.

Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023

Xeris Biopharma said it has shipped more than 1 million units of Gvoke, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children aged two years and older with diabetes. “We are proud to celebrate this major milestone of having shipped over 1 million units of Gvoke since its launch,” Xeris CEO Paul R.

Xeris Biopharma achieves shipping milestone for hypoglycemia treatment Gvoke

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that Xeris has shipped more than one million units of Gvoke® – the company's ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. “We are proud to celebrate this majo.

Xeris Ships One Millionth Gvoke® Unit

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that the first participant has been dosed in a multi-center, open-label, Phase 2 study of XP-8121 (levothyroxine sodium) for the treatment of adults with hypothyroidism. The biopharmaceutical company explained that the Phase 2 study (NCT05823012) is a non-randomized, open-label, single-arm, self-controlled study of XP-8121.

Xeris Biopharma says first participant dosed in Phase 2 clinical study of investigational subcutaneous levothyroxine in patients with hypothyroidism

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the first participant has been dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidism. “Oral levothyroxine is one of the most prescribed medicines in the United States, generating more.

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, such as Glucagon and Gvoke, and is aggressively securing patents to stay ahead of competition. XERS is expected to achieve profitability soon, with a breakeven cash flow by Q4 2023, and an estimated EPS of $0.23 by 2026.

Xeris Biopharma: Remarkable Market Share Expansion

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 10:30am Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' sect.

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Glen Santangelo - Jefferies Roanna Ruiz - SVB Securities Operator Hello all and warm welcome to the Xeris Biopharma Holding First Quarter 2023 Financial Results Call.

Xeris Biopharma Holdings, Inc. (XERS) Q1 2023 Earnings Call Transcript

Xeris Biopharma Holdings (NASDAQ:XERS) has started 2023 strongly, achieving record revenue during the first quarter.   For the quarter ended March 31, 2023, revenue rose 50.4% to $33.2 million from $22 million in the first quarter of 2022.

Xeris Biopharma posts record revenue in 1Q

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2023, and other corporate highlights. “We had a very strong start to 2023 with record total revenue, strong underlying patient demand in all three commercial products, and the addition of.

Xeris Biopharma Reports First Quarter 2023 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, May 9, 2023. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the C.

Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023

Xeris Biopharma Holdings (NASDAQ:XERS) said it has received a US patent covering formulations in its Gvoke product line used to treat severe hypoglycemia.  The patent issued by the US Patent and Trademark Office covers methods for using the formulations in treating hypoglycemia as well as manufacturing methods, the biopharma company said.

Xeris Biopharma secures US patent for XeriSol formulations

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.

Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the agreement, the company said it will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small-volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron.  Xeris will receive an upfront payment and potential milestone payments for preclinical achievements.

Xeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJect

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc.

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™

Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced the appointment of Ricki Fairley to its board of directors on March 27, 2023, increasing the size of the company's board to nine members. The growth-oriented biopharmaceutical firm said Fairley has over 35 years of marketing experience including 20 years in brand management at Johnson & Johnson (NYSE:JNJ), Nabisco, Reckitt & Colman, and The Coca-Cola Company (NYSE:KO).

Xeris Biopharma appoints brand management expert Ricki Fairley to its board of directors

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board to nine members, on March 27, 2023.

News for Xeris Biopharma Holdings Stock (XERS)